// App-Quantinova.ai

E088 : Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis

Researchers

Presenter

  • Bruce Strober

Principal Investigators

  • Laura Coates

  • Jenny Yu

  • Katelyn Rowland

  • Evan Leibowitz

  • Megan Miller

  • Alexa Kollmeier

  • Shu Li

  • Yanli Wang

  • Daphne Chan

  • Soumya Chakravarty

  • Ya-Wen Yang

  • May Shawi

  • Mark Lebwohl

  • Proton Rahman

Medical Centers

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Dermatology, Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT

  • Rheumatology and Musculoskeletal Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

  • Rheumatology and Musculoskeletal Sciences, Memorial University, NL, Canada, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved